Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial

BACKGROUND: Rituximab is effective as therapy for induction of remission in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and subsequent relapse rates are high, especially in patients with a history of relapse. There is a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Trials
Main Authors: Gopaluni, Seerapani, Smith, Rona M., Lewin, Michelle, McAlear, Carol A., Mynard, Kim, Jones, Rachel B., Specks, Ulrich, Merkel, Peter A., Jayne, David R. W.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5341185/
https://ncbi.nlm.nih.gov/pubmed/28270229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-017-1857-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados